Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma

Phase 2 Terminated 6 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NaSingle-groupOpen-labelTreatment

Summary

The primary goal of the trail was to determine the efficacy of combining Gemcitabine and Docetaxel in treatment of metastatic colorectal cancer with CHFR and/or Microsatellite Instability (MSI) phenotype.

Timeline

Start: 2012-09-10
Primary completion: 2016-10-03
Completion: 2019-03-11

Publications

Baretti M, Karunasena E, Zahurak M, Walker R, Zhao Y, Pisanic TR 2nd, Wang TH, Greten TF, Duffy AG, Gootjes E, Meijer G, Verheul HMW, Ahuja N, Herman JG, Azad NS. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clin Transl Sci. 2021 May;14(3):954-963. doi: 10.1111/cts.12960. Epub 2021 Apr 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	70 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	800 mg/m2	Intravenous
Background	Pegfilgrastim	Protein / enzyme biologic	6 mg	—
Background	filgrastim	Protein / enzyme biologic	—	—

Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications